source
- Novartis board under fire as two late-stage trials fail and CAR-T program pausedNovartis' board is facing heightened investor scrutiny after the Swiss drugmaker reported failures in two pivotal late-phase trials, raising doubts about its capital deployment strategy for growth…
- Samsung Biologics secures $262 million manufacturing contract with European pharma firmSamsung Biologics announced a $262 million agreement to provide manufacturing services to an unnamed European pharmaceutical company. The contract runs through 2033. The deal will be executed at S…